title: IL-17 targeted therapies for psoriasis.
abstract: BACKGROUND
  Psoriasis is a chronic, disabling, inflammatory skin disease whose pathogenesis still remains to be fully elucidated. Genetic and environmental factors induce an immune response mediated by several cytokines and chemokines, including IL-17A.
  
  
  METHODS
  Emerging evidence now suggests that IL-17A is central in the pathogenesis of psoriasis. Three agents neutralizing IL-17 (i.e., secukinumab and ixekizumab) or antagonizing its receptor (i.e., brodalumab) are in development and are being studied in Phase III clinical trials to evaluate their overall efficacy and safety. However, Phase II results of IL-17 blockade with each of these agents has shown a marked improvement of disease severity, thus confirming the pathogenic relevance of IL-17 in mediating crucial inflammatory circuits in psoriasis.
  
  
  CONCLUSIONS
  Anti-IL-17 agents are likely to become important future therapeutics in this disease and the may potentially impact on cardiovascular diseases, arthritis and other comorbidities associated with psoriasis.
authors.affiliation: The Rockefeller University, Laboratory for Investigative Dermatology , 1230 York Avenue, New York City, NY 10065, USA. chiricozziandrea@gmail.com
authors.forename: Andrea
authors.initials: A
authors.lastname: Chiricozzi
authors.forename: James G
authors.initials: JG
authors.lastname: Krueger
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001685:Biological Factors / Q000627:therapeutic use; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D059467:Transcriptome
chemical_list: D000911:Antibodies, Monoclonal; D001685:Biological Factors; D020381:Interleukin-17